DCC5412 |
Vicagrel |
Clopidogrel analog as an antiplatelet agent |
|
DCC5413 |
Vidarabine Monohydrate |
Broad spectrum antibiotic, inhibiting adenylyl cyclase type 5 (AC5) and protecting against chronic coronary artery occlusion (CAO) |
|
DCC5414 |
Vilanterol |
Selective long-acting beta2-adrenergic agonist (LABA) with inherent 24-hour activity for once daily treatment of COPD and asthma |
|
DCC5415 |
Vincamine V2a |
Novel antagonist against hypocretin (orexin) receptor 2, significantly preventing acute morphine-conditioned place preference (CPP) and stress-induced reinstatement of extinguished morphine-CPP in mouse models of opioid reward and relapse |
|
DCC5416 |
Vincapusine |
Natural inhibitor of 3C-like protease (3CLpro), targeting SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro |
|
DCC5417 |
Vincetoxicoside A |
Natural antimicrobial, antioxidant, and anti-inflammator agent |
|
DCC5418 |
Virodhamine Trifluoroacetate |
Endogenous cannabinoid receptor mixed agonist/antagonist, being a full agonist at GPR55 and CB2 and partial agonist/antagonist at CB1 |
|
DCC5419 |
Vitexin 4"-o-glucoside |
Natural inhibitor of ST2 (IL1RL1) |
|
DCC5420 |
Viviren |
Coelenterazine analog for bioluminescence imaging (BLI) |
|
DCC5421 |
Vmy-1-101 |
Fluorescent cyclin-dependent kinase inhibitor, blocking the proliferation of human breast cancer cells |
|
DCC5422 |
vmy-2-95 |
Novel and selective desensitizer of |
|
DCC5423 |
Setmelanotide Tfa Salt
Featured
|
Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals |
|
DCC5424 |
Voa Analog 19 |
Novel potent VEGFR2 modulator, exhibiting increased antiangiogenic potency than voacangine against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects, resulting in significant tumor cell death in a mouse xenograft model |
|
DCC5425 |
Voclosporin |
Novel calcineurin inhibitor and immunosuppressive agent |
|
DCC5426 |
Vonoprazan Fumurate |
Novel potassium-competitive acid blocker |
|
DCC5427 |
Vpc-00628 |
Novel potent and highly selective type-II inhibitor of p38α/β, targeting an inactive state of the kinases induced by a unique folded P-loop conformation |
|
DCC5428 |
Vpc-13163 |
Potent Antiandrogen, Targeting the BF3 Site of the Androgen Receptor and Inhibiting Enzalutamide-Resistant Prostate Cancer |
|
DCC5429 |
Vpc-16606 |
Novel potent and selective inhibitor of ERα-dependent cell growth and gene expression, preventing the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner |
|
DCC5430 |
Vpc24191 |
S1P1/S1P3 receptor agonist |
|
DCC5431 |
Vpc-3033 |
Novel Androgen Receptor Antagonist, inhibiting the LNCaP cell line as well as cell lines with wild-type androgen receptor |
|
DCC5432 |
Vpc44116 |
Competitive S1P1/3 antagonist, increasing capillary permeability as measured by Evans blue dye leakage in mouse lung tissue |
|
DCC5433 |
Vrt-325 |
Corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant |
|
DCC5434 |
Vrv-pl-viiia Inhibitor 5m |
Inhibitor of the catalytic activity of VRV-PL-VIIIa, strongly inhibiting the hemolysis of red blood cells and VRV-PL-VIIIa-induced myotoxicity and lung hemorrhage in mice |
|
DCC5435 |
Vrx-480773 |
Novel Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) |
|
DCC5436 |
Vsw1198 |
Novel inhibitor of geranylgeranyl diphosphate synthase (GGDPS) |
|
DCC5437 |
Vswrapta |
Novel Promoter of Neuronal Branching Via Transcellular Activation of the Focal Adhesion Kinase (FAK) and the ERK1/2 Signaling Pathway In Vitro |
|
DCC5438 |
Vt-me6 |
Sphingosine kinase (SphK) inhibitor, having modest SphK2-selectivity |
|
DCC5439 |
Vtx-2337 Analog-1 |
Novel selective agonist of TLR8 |
|
DCC5440 |
Vu0034403 |
Novel non-MPEP site metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) |
|
DCC5441 |
Vu0160573 |
Selective modulator of G protein-coupled inward rectifier K (GIRK) |
|